BioNTech Secures UK Government Grant for R&D Expansion

TL;DR

BioNTech UK lands UK gov grant to boost R&D.

AI Summary

On May 20, 2025, BioNTech SE announced that its subsidiary, BioNTech UK Ltd., has entered into a grant agreement with the UK Government. This agreement aims to expand the company's research and development capabilities in the United Kingdom.

Why It Matters

This grant signifies government support for BioNTech's innovation in the UK, potentially accelerating the development of new therapies and strengthening its presence in the region.

Risk Assessment

Risk Level: low — The filing is an announcement of a grant agreement, which is generally a positive development with low immediate risk.

Key Players & Entities

• BioNTech SE (company) — Registrant
• BioNTech UK Ltd. (company) — Subsidiary signing grant agreement
• UK Government (company) — Grantor
• May 20, 2025 (date) — Announcement date

FAQ

From the Filing

0001776985-25-000035.txt : 20250520 0001776985-25-000035.hdr.sgml : 20250520 20250520085801 ACCESSION NUMBER: 0001776985-25-000035 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250520 FILED AS OF DATE: 20250520 DATE AS OF CHANGE: 20250520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25966412 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kukgrant20may2025.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MAY 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On May 20, 2025, BioNTech SE (“the Company”) announced that its subsidiary BioNTech UK Ltd. signed a grant agreement with the UK Government to broaden the Company’s R&D activities for innovative medicines in the UK. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: May 20, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Expands Partnership with UK Government to Broaden Regional Research and Development Activities EX-99.1 2 a991250519_bntxxukgrantxpr.htm EX-99.1 Document Exhibit 99.1 BioNTech Expands Partnership with UK Government to Broaden Regional Research and Development Activities • BioNTech plans to invest up to £1 billion over the next 10 years to broaden its research and development activities for innovative medicines in the United Kingdom (“UK”) • The UK Government will give BioNTech a grant of up to £129 million payable over a period of 10 years to support BioNTech’s research and development activities in the UK, marking one of the largest grants of its kind in UK history for a pharmaceutical company • Grant agreement builds on existing multi-year collaboration with the UK Government aimed at benefiting patients by accelerating clinical trials for personalized mRNA immunotherapies and focuses on establishing two new Research and Development (“R&D”) centers and a UK headquarters in London, accommodating BioNTech’s artificial intelligence (“AI”) hub MAINZ, Germany, May 20, 2025  -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that its subsidiary BioNTech UK Ltd. signed a grant agreement with the UK Government to broaden the Company’s R&